ABSTRACT
OBJECTIVE:To systematically review the efficacy and safety of Ambrette capsule combined with Tripterygium gly-cosides tablet versus Tripterygium glycosides tablet alone in the treatment of diabetic nephropathy to provide evidence-based refer-ence for clinical treatment. METHODS:Retrieved from CJFD,Wanfang database,VIP database,Cochrane Library,EMBase and Medline randomized controlled trials(RCT)about Ambrette capsule combined with Tripterygium glycosides tablet(test group)ver-sus Tripterygium glycosides tablet alone(control group)in the treatment of diabetic nephropathy were collected. Meta-analysis was performed by using Rev Man 5.1 software after data extraction and quality evaluation. RESULTS:A total of 5 RCTs were includ-ed,involving 400 patients. Results of Meta-analysis showed the effective rate [OR=4.10,95%CI(2.27,7.38),P<0.001],24 h uri-nary protein quantificative value[MD=-0.54,95%CI(-0.72,-0.36),P<0.001] in test group were significantly higher than con-trol group,there were statistical significances. alanine aminotransferase value [MD=0.14,95%CI(-1.08,1.36),P=0.82] and changes value of peripheral white blood cells(WBC)[MD=-0.31,95%CI(-0.64,0.03),P=0.07] were not statistical difference between 2 groups. CONCLUSIONS:Efficacy of Ambrette capsule combined with Tripterygium glycosides tablet in the treatment of diabetic nephropathy were superior to Tripterygium glycosides tablet alone with similar safety. Due to limit of methodological quali-ty,more strict,long-term follow-up large-scale RCTs were required to validate the conclusion.
ABSTRACT
Objective To observe the clinical effects of irbesartan combined with ambrette capsule for treatment of mild-to-moderate proteinuria in type 2 diabetic nephropathy. Methods Foutty-six patients with diabetic nephropathy( DN),who meet the diagnostic criteria for diabetes and DN diagnostic criteria which WHO promulgated in 1999 years,were randomly divided into control group(n =23)and treatment group(n =23) . Patients in control group were administrated conventional hypoglycemic drugs,lipid,calcium antagonists step-down and diet control,while in treatment group were administrated irbesartan(75 mg,1 times/d)combined with ambrette capsule(5 pills,3 times/d)on this basis. Both the treatment duration was 8 weeks. Urine protein,blood urea nitrogen( BUN),serum creatinine( SCr)and C reactive protein( CRP)were measured respectively before treatment and 8 weeks after treatment. Results After 8 weeks treatment,the total effective rate in treatment group was 87. 0%(20/23),higher than that of control group(52. 2%(12/23);χ2 =6. 571,P﹤0. 05). The CRP had decreased significantly in treatment group( from( 11. 7 ± 0. 9 ) mg/L to( 5. 8 ± 0. 3 ) mg/L ) which compared with control group(from(10. 1 ± 0. 6)mg/Lto(9. 8 ± 0. 4)mg/L;P﹤0. 05). But BUN and SCr had no significant difference compared with pre-treatment( P ﹥ 0. 05 ). Conclusion Irbesartan combine with ambrette capsule can significantly decrease the urine protein and regulate on the micro-inflammatory state. It is worthy of popularization and application.